Indoco Remedies Ltd. announced the receipt of tentative approval from the USFDA for Abbreviated New Drug Application (ANDA) for Canagliflozin and Metformin Hydrochloride Tablets, 50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg and 150 mg/1000 mg, a generic equivalent of Invokamet® Tablets, 50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg and 150 mg/1000 mg. This product, Canagliflozin and Metformin Hydrochloride Tablets, will be manufactured by Indoco Remedies Limited, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa 403722 in India. Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
327 INR | +0.57% | +0.28% | -17.24% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.24% | 361M | |
+51.63% | 796B | |
+41.51% | 628B | |
-5.10% | 358B | |
+19.90% | 331B | |
+9.95% | 301B | |
+17.66% | 244B | |
+3.39% | 228B | |
+10.75% | 214B | |
+6.99% | 165B |
- Stock Market
- Equities
- INDOCO Stock
- News Indoco Remedies Limited
- Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets